6 月 4 日,阿斯利康宣布,英飞凡®(通用名:度伐利尤单抗)已获 NMPA 批准,作为单药用于在接受铂类药物为基础的放化疗后未出现疾病进展的局限期小细胞肺癌(LS-SCLC)成人患者的治疗。截图来源:企业官网新闻稿指出,此次获批意味着度伐利尤单抗已成为中国首个且唯一同时获批用于局限期与广泛期小细胞肺癌的免疫治疗药物。此外,本次获批是基于 ADRIATIC III 期临床试验的积极结果。此前,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.